These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 31779670)

  • 21. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers.
    Suárez-Calvet M; Kleinberger G; Araque Caballero MÁ; Brendel M; Rominger A; Alcolea D; Fortea J; Lleó A; Blesa R; Gispert JD; Sánchez-Valle R; Antonell A; Rami L; Molinuevo JL; Brosseron F; Traschütz A; Heneka MT; Struyfs H; Engelborghs S; Sleegers K; Van Broeckhoven C; Zetterberg H; Nellgård B; Blennow K; Crispin A; Ewers M; Haass C
    EMBO Mol Med; 2016 May; 8(5):466-76. PubMed ID: 26941262
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Soluble TREM2 is elevated in Parkinson's disease subgroups with increased CSF tau.
    Wilson EN; Swarovski MS; Linortner P; Shahid M; Zuckerman AJ; Wang Q; Channappa D; Minhas PS; Mhatre SD; Plowey ED; Quinn JF; Zabetian CP; Tian L; Longo FM; Cholerton B; Montine TJ; Poston KL; Andreasson KI
    Brain; 2020 Mar; 143(3):932-943. PubMed ID: 32065223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum.
    Rauchmann BS; Schneider-Axmann T; Alexopoulos P; Perneczky R;
    Neurobiol Aging; 2019 Feb; 74():182-190. PubMed ID: 30458365
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dynamic changes of CSF sTREM2 in preclinical Alzheimer's disease: the CABLE study.
    Ma LZ; Tan L; Bi YL; Shen XN; Xu W; Ma YH; Li HQ; Dong Q; Yu JT
    Mol Neurodegener; 2020 Apr; 15(1):25. PubMed ID: 32276587
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biological correlates of elevated soluble TREM2 in cerebrospinal fluid.
    Winfree RL; Dumitrescu L; Blennow K; Zetterberg H; Gifford KA; Pechman KR; Jefferson AL; Hohman TJ;
    Neurobiol Aging; 2022 Oct; 118():88-98. PubMed ID: 35908327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An Altered Relationship between Soluble TREM2 and Inflammatory Markers in Young Adults with Down Syndrome: A Preliminary Report.
    Weber GE; Koenig KA; Khrestian M; Shao Y; Tuason ED; Gramm M; Lal D; Leverenz JB; Bekris LM
    J Immunol; 2020 Mar; 204(5):1111-1118. PubMed ID: 31959733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Andreasson U; Zetterberg H; Blennow K;
    JAMA Neurol; 2017 May; 74(5):557-566. PubMed ID: 28346578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration.
    Franzmeier N; Suárez-Calvet M; Frontzkowski L; Moore A; Hohman TJ; Morenas-Rodriguez E; Nuscher B; Shaw L; Trojanowski JQ; Dichgans M; Kleinberger G; Haass C; Ewers M;
    Mol Neurodegener; 2020 Oct; 15(1):57. PubMed ID: 33032659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury.
    Suárez-Calvet M; Araque Caballero MÁ; Kleinberger G; Bateman RJ; Fagan AM; Morris JC; Levin J; Danek A; Ewers M; Haass C;
    Sci Transl Med; 2016 Dec; 8(369):369ra178. PubMed ID: 27974666
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer's disease model.
    Zhong L; Xu Y; Zhuo R; Wang T; Wang K; Huang R; Wang D; Gao Y; Zhu Y; Sheng X; Chen K; Wang N; Zhu L; Can D; Marten Y; Shinohara M; Liu CC; Du D; Sun H; Wen L; Xu H; Bu G; Chen XF
    Nat Commun; 2019 Mar; 10(1):1365. PubMed ID: 30911003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of Cerebrospinal Fluid Soluble TREM2 and Polymorphisms in Sporadic Parkinson's Disease in a Chinese Population.
    Peng G; Qiu J; Liu H; Zhou M; Huang S; Guo W; Lin Y; Chen X; Li Z; Li G; Zhang W; Zhang Y; Li X; Wu Z; Wei L; Yang X; Zhu X; Mo M; Xu P
    J Mol Neurosci; 2020 Feb; 70(2):294-301. PubMed ID: 31833018
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Soluble TREM2: Innocent bystander or active player in neurological diseases?
    Filipello F; Goldsbury C; You SF; Locca A; Karch CM; Piccio L
    Neurobiol Dis; 2022 Apr; 165():105630. PubMed ID: 35041990
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TREM2 splice isoforms generate soluble TREM2 species that disrupt long-term potentiation.
    Moutinho M; Coronel I; Tsai AP; Di Prisco GV; Pennington T; Atwood BK; Puntambekar SS; Smith DC; Martinez P; Han S; Lee Y; Lasagna-Reeves CA; Lamb BT; Bissel SJ; Nho K; Landreth GE
    Genome Med; 2023 Feb; 15(1):11. PubMed ID: 36805764
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Soluble TREM2 inhibits secondary nucleation of Aβ fibrillization and enhances cellular uptake of fibrillar Aβ.
    Belsare KD; Wu H; Mondal D; Bond A; Castillo E; Jin J; Jo H; Roush AE; Pilla KB; Sali A; Condello C; DeGrado WF
    Proc Natl Acad Sci U S A; 2022 Feb; 119(5):. PubMed ID: 35082148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Soluble TREM2 in body fluid in Alzheimer's disease and Parkinson's disease.
    Gu L; Shu H; Wang Y
    Neurol Sci; 2023 Aug; 44(8):2743-2751. PubMed ID: 36913148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TREMs in Alzheimer's disease: Genetic and clinical investigations.
    Cheng J; Guo X; Zhang T; Zhong L; Bu G; Chen X
    Clin Chim Acta; 2016 Dec; 463():88-95. PubMed ID: 27769848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Soluble TREM2 ameliorates tau phosphorylation and cognitive deficits through activating transgelin-2 in Alzheimer's disease.
    Zhang X; Tang L; Yang J; Meng L; Chen J; Zhou L; Wang J; Xiong M; Zhang Z
    Nat Commun; 2023 Oct; 14(1):6670. PubMed ID: 37865646
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glial activation and inflammation along the Alzheimer's disease continuum.
    Nordengen K; Kirsebom BE; Henjum K; Selnes P; Gísladóttir B; Wettergreen M; Torsetnes SB; Grøntvedt GR; Waterloo KK; Aarsland D; Nilsson LNG; Fladby T
    J Neuroinflammation; 2019 Feb; 16(1):46. PubMed ID: 30791945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Soluble TREM2, Alzheimer's Disease Pathology, and Risk for Progression of Cerebral Small Vessel Disease: A Longitudinal Study.
    Wu C; Ma YH; Hu H; Zhao B; Tan L;
    J Alzheimers Dis; 2023; 92(1):311-322. PubMed ID: 36744335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased expression of TREM2 in peripheral blood of Alzheimer's disease patients.
    Hu N; Tan MS; Yu JT; Sun L; Tan L; Wang YL; Jiang T; Tan L
    J Alzheimers Dis; 2014; 38(3):497-501. PubMed ID: 24002183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.